{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:51:56Z","timestamp":1790779916422,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030E-160403\/1"],"award-info":[{"award-number":["310030E-160403\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030E-182872\/1"],"award-info":[{"award-number":["310030E-182872\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["DOC 33-B27"],"award-info":[{"award-number":["DOC 33-B27"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001822","name":"\u00d6sterreichischen Akademie der Wissenschaften","doi-asserted-by":"publisher","award":["DOC fellowship"],"award-info":[{"award-number":["DOC fellowship"]}],"id":[{"id":"10.13039\/501100001822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001822","name":"\u00d6sterreichischen Akademie der Wissenschaften","doi-asserted-by":"publisher","award":["DOC fellowship"],"award-info":[{"award-number":["DOC fellowship"]}],"id":[{"id":"10.13039\/501100001822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The NMDA receptor (NMDAR) plays a key role in the central nervous system, e.g., for synaptic transmission. While synaptic NMDARs are thought to have protective characteristics, activation of extrasynaptic NMDARs might trigger excitotoxic processes linked to neuropsychiatric disorders. Since extrasynaptic NMDARs are typically GluN2B-enriched, the subunit is an interesting target for drug development and treatment monitoring. Recently, the novel GluN2B-specific PET radioligand <jats:italic>(R)<\/jats:italic>-[<jats:sup>11<\/jats:sup>C]Me-NB1 was investigated in rodents and for the first time successfully translated to humans. To assess whether <jats:italic>(R)<\/jats:italic>-[<jats:sup>11<\/jats:sup>C]Me-NB1 is a valuable radioligand for (repeated) clinical applications, we evaluated its safety, biodistribution and dosimetry.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Four healthy subjects (two females, two males) underwent one whole-body PET\/MR measurement lasting for more than 120\u00a0min. The GluN2B-specific radioligand <jats:italic>(R)<\/jats:italic>-[<jats:sup>11<\/jats:sup>C]Me-NB1 was administered simultaneously with the PET start. Subjects were measured in nine passes and six bed positions from head to mid-thigh. Regions of interest was anatomically defined for the brain, thyroid, lungs, heart wall, spleen, stomach contents, pancreas, liver, kidneys, bone marrow and urinary bladder contents, using both PET and MR images. Time-integrated activity coefficients were estimated to calculate organ equivalent dose coefficients and the effective dose coefficient. Additionally, standardized uptake values (SUV) were computed to visualize the biodistribution.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Administration of the radioligand was safe without adverse events. The organs with the highest uptake were the urinary bladder, spleen and pancreas. Organ equivalent dose coefficients were higher in female in almost all organs, except for the urinary bladder of male. The effective dose coefficient was 6.0 \u00b5Sv\/MBq.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The GluN2B-specific radioligand <jats:italic>(R)<\/jats:italic>-[<jats:sup>11<\/jats:sup>C]Me-NB1 was well-tolerated without reported side effects. Effective dose was estimated to 1.8\u00a0mSv when using 300\u00a0MBq of presented radioligand. The critical organ was the urinary bladder. Due to the low effective dose coefficient of this radioligand, longitudinal studies for drug development and treatment monitoring of neuropsychiatric disorders including neurodegenerative diseases are possible.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> Registered on 11th of June 2019 at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.basg.gv.at\">https:\/\/www.basg.gv.at<\/jats:ext-link> (EudraCT: 2018-002933-39).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13550-022-00925-8","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T13:03:04Z","timestamp":1661518984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[11C]Me-NB1"],"prefix":"10.1186","volume":"12","author":[{"given":"Lucas","family":"Rischka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matej","family":"Murga\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysoula","family":"Vraka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Nics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sazan","family":"Rasul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo Robert","family":"Silberbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray Bruce","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godber Mathis","family":"Godbersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Unterholzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Handschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Gryglewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Mitterhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Mensah","family":"Ametamey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Wadsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4641-9539","authenticated-orcid":false,"given":"Rupert","family":"Lanzenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"925_CR1","first-page":"7","volume":"51","author":"R Dingledine","year":"1999","unstructured":"Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev. 1999;51:7\u201361.","journal-title":"Pharmacol Rev"},{"key":"925_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrn3504","volume":"14","author":"P Paoletti","year":"2013","unstructured":"Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: Impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 2013;14:383\u2013400.","journal-title":"Nat Rev Neurosci"},{"key":"925_CR3","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nrn2911","volume":"11","author":"GE Hardingham","year":"2010","unstructured":"Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11:682\u201396.","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"925_CR4","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/JCP.0b013e31825d70d6","volume":"32","author":"L Ibrahim","year":"2012","unstructured":"Ibrahim L, Diazgranados N, Jolkovsky L, Brutsche N, Luckenbaugh DA, Joseph Herring W, et al. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol. 2012;32(4):551\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"925_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pneurobio.2015.12.001","volume":"152","author":"R Machado-Vieira","year":"2017","unstructured":"Machado-Vieira R, Henter ID, Zarate CA. New targets for rapid antidepressant action. Progress Neurobiol. 2017;152:21\u201337.","journal-title":"Progress Neurobiol"},{"issue":"8","key":"925_CR6","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.2967\/jnumed.118.221051","volume":"60","author":"A Haider","year":"2019","unstructured":"Haider A, Herde AM, Kr\u00e4mer SD, Varisco J, Keller C, Frauenknecht K, et al. Preclinical evaluation of benzazepine-based PET radioligands (R)- And (S)-11C-Me-NB1 reveals distinct enantiomeric binding patterns and a tightrope walk between GluN2B- And S1-receptor\u2013targeted PET imaging. J Nucl Med. 2019;60(8):1167\u201373.","journal-title":"J Nucl Med"},{"key":"925_CR7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262427","author":"L Rischka","year":"2021","unstructured":"Rischka L, Vraka C, Pichler V, Rasul S, Nics L, Gryglewski G, et al. First-in-human brain PET imaging of the GluN2B-containing N-methyl-D-aspartate receptor with (R)-11 C-Me-NB1. J Nucl Med. 2021. https:\/\/doi.org\/10.2967\/jnumed.121.262427.","journal-title":"J Nucl Med"},{"issue":"7","key":"925_CR8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2967\/jnumed.115.156000","volume":"56","author":"DH Paulus","year":"2015","unstructured":"Paulus DH, Quick HH, Geppert C, Fenchel M, Zhan Y, Hermosillo G, et al. Whole-body PET\/MR imaging: quantitative evaluation of a novel model-based MR attenuation correction method including bone. J Nucl Med. 2015;56(7):1061\u20136.","journal-title":"J Nucl Med"},{"issue":"1","key":"925_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13550-019-0527-4","volume":"9","author":"A Johansen","year":"2019","unstructured":"Johansen A, Holm S, Dall B, Keller S, Kristensen JL, Knudsen GM, et al. Human biodistribution and radiation dosimetry of the 5-HT2A receptor agonist Cimbi-36 labeled with carbon-11 in two positions. EJNMMI Res. 2019;9(1):71.","journal-title":"EJNMMI Res"},{"issue":"1","key":"925_CR10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2967\/jnumed.117.196261","volume":"59","author":"MG Stabin","year":"2018","unstructured":"Stabin MG, Siegel JA. RADAR dose estimate report: A Compendium of radiopharmaceutical dose estimates based on OLINDA\/EXM version 2.0. J Nucl Med. 2018;59(1):154\u201360.","journal-title":"J Nucl Med"},{"key":"925_CR11","unstructured":"ICRP. Annals of the ICRP Published on behalf of the International Commission on Radiological Protection International Commission on Radiological Protection Main Commission of the ICRP Corresponding members. Ann ICRP. 2007;103."},{"issue":"4","key":"925_CR12","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s11307-010-0398-6","volume":"13","author":"S Bullich","year":"2011","unstructured":"Bullich S, Slifstein M, Passchier J, Murthy NV, Kegeles LS, Kim JH, et al. Biodistribution and radiation dosimetry of the glycine transporter-1 ligand 11C-GSK931145 determined from primate and human whole-body PET. Mol Imaging Biol. 2011;13(4):776\u201384.","journal-title":"Mol Imaging Biol"},{"issue":"2","key":"925_CR13","first-page":"313","volume":"47","author":"M Slifstein","year":"2006","unstructured":"Slifstein M, Hwang DR, Martinez D, Ekelund J, Huang Y, Hackett E, et al. Biodistribution and radiation dosimetry of the dopamine D2 ligand 11C-raclopride determined from human whole-body PET. J Nucl Med. 2006;47(2):313\u20139.","journal-title":"J Nucl Med"},{"issue":"1","key":"925_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.nucmedbio.2013.08.008","volume":"41","author":"Y Kimura","year":"2014","unstructured":"Kimura Y, Ito H, Shiraishi T, Fujiwara H, Kodaka F, Takano H, et al. Biodistribution and radiation dosimetry in humans of [11C]FLB 457, a positron emission tomography ligand for the extrastriatal dopamine D2 receptor. Nucl Med Biol. 2014;41(1):102\u20135.","journal-title":"Nucl Med Biol"},{"issue":"4","key":"925_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.nucmedbio.2007.02.005","volume":"34","author":"MJ Ribeiro","year":"2007","unstructured":"Ribeiro MJ, Ricard M, Li\u00e8vre MA, Bourgeois S, Emond P, Gervais P, et al. Whole-body distribution and radiation dosimetry of the dopamine transporter radioligand [11C]PE2I in healthy volunteers. Nucl Med Biol. 2007;34(4):465\u201370.","journal-title":"Nucl Med Biol"},{"issue":"3","key":"925_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.nucmedbio.2013.12.007","volume":"41","author":"M Persson","year":"2014","unstructured":"Persson M, El Ali HH, Binderup T, Pfeifer A, Madsen J, Rasmussen P, et al. Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging. Nucl Med Biol. 2014;41(3):290\u20135.","journal-title":"Nucl Med Biol"},{"issue":"4","key":"925_CR17","first-page":"608","volume":"46","author":"G Brix","year":"2005","unstructured":"Brix G, Lechel U, Glatting G, Ziegler SI, M\u0308nzing W, M\u00fcller SP, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET\/CT examinations. J Nucl Med. 2005;46(4):608\u201313.","journal-title":"J Nucl Med"},{"key":"925_CR18","doi-asserted-by":"publisher","unstructured":"Towson JEC. Radiation Dosimetry and Protection in PET. In: Positron Emission Tomography. Springer, London; 2006. p. 251\u201365. Available from: https:\/\/link.springer.com\/chapter\/https:\/\/doi.org\/10.1007\/1-84628-007-9_12","DOI":"10.1007\/1-84628-007-9_12"},{"issue":"1","key":"925_CR19","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41598-021-81002-3","volume":"11","author":"M Hatano","year":"2021","unstructured":"Hatano M, Miyazaki T, Ishiwata Y, Nakajima W, Arisawa T, Kuroki Y, et al. Biodistribution and radiation dosimetry of the positron emission tomography probe for AMPA receptor, [11C]K-2, in healthy human subjects. Sci Rep. 2021;11(1):1598.","journal-title":"Sci Rep"},{"key":"925_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2967\/jnumed.120.257402","volume":"62","author":"P Zanotti-Fregonara","year":"2021","unstructured":"Zanotti-Fregonara P, Lammertsma AA, Innis RB. 11C dosimetry scans should be abandoned. J Nucl Med. 2021;62:158\u20139.","journal-title":"J Nucl Med"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-022-00925-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-022-00925-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-022-00925-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T13:11:18Z","timestamp":1661519478000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-022-00925-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1186\/s13550-022-00925-8","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"assertion":[{"value":"19 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee (ethics number: 1980\/2018) of the Medical University of Vienna. Procedures were carried out in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All subjects gave written informed consent after detailed explanation of the study procedure.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S. M.\u00a0Ametamey is co-inventor of the filed patent number US2017\/0224852A1. R. Lanzenberger received travel grants and\/or conference speaker honoraria within the last three years from Bruker BioSpin MR and support from Siemens Healthcare regarding clinical research using PET\/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. D. Winkler received lecture fees\/authorship honoraria within the last three years from Angelini, Lundbeck, MedMedia Verlag, and Medical Dialogue. Without relevance to this work, W. Wadsak received within the last 3\u00a0years research grants from ITM Medical Isotopes GmbH (Munich, Germany) and Scintomics (F\u00fcrstenfeldbruck, Germany). Without relevance to this work, M. Mitterhauser is scientific advisor for ROTOP Pharma GmbH. All other authors declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}